



RATIONALE FOR INCLUSION IN PA PROGRAM

Background

Trulance (plecanatide) is a guanylate cyclase-C (GC-C) agonist. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP). Elevation of intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit (1).

Regulatory Status

FDA-approved indications: Trulance is a guanylate cyclase-C agonist indicated in adults for treatment of: (1)

1. Chronic idiopathic constipation (CIC)
2. Irritable bowel syndrome with constipation (IBS-C)

Trulance has a boxed warning for children under the age of 6 due to risk of serious dehydration. Avoid use of Trulance in patients 6 years to less than 18 years of age (1).

The use of this medication is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction (1).

Safety and effectiveness in pediatric patients less than 18 years of age has not been established, avoid the use of Trulance in patients 6 years to less than 18 years of age (1).

Summary

Trulance (plecanatide) is a guanylate cyclase-C (GC-C) agonist. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP), eventually resulting in increased intestinal fluid and accelerated transit. Trulance is indicated in adults for treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Trulance while maintaining optimal therapeutic outcomes.

References



**BlueCross
BlueShield**

Federal Employee Program.

**TRULANCE
(plecanatid)**

1. Trulance [package insert]. Bridgewater, NJ: Salix Pharmaceuticals; March 2024.